Sign In
Buy PLSE
$24.99
+0.710 (+2.92%)
At Close: Jun 03, 2026
Argo Wealth Advisory LLC Makes New $387,000 Investment in Pulse Biosciences, Inc $PLSE
03:28am, Friday, 17'th Apr 2026
Argo Wealth Advisory LLC acquired a new position in Pulse Biosciences, Inc (NASDAQ: PLSE) during the undefined quarter, according to the company in its most recent 13F filing with the Securities and E
Pulse Biosciences Initiates Patient Enrollment in NANOPULSE-AF Study
10:51am, Monday, 13'th Apr 2026
PLSE begins patient enrollment in NANOPULSE-AF pivotal study, advancing its NPS tech toward potential AF treatment approval and entry into a large cardiac market.
Pulse Biosciences Strengthens Executive Leadership Team
07:00am, Thursday, 09'th Apr 2026
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, today announced the st
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, today announced enroll
Pulse Biosciences to Present at the 25th Annual Needham Virtual Healthcare Conference
04:05pm, Thursday, 02'nd Apr 2026
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), pioneer of the novel nPulse™ platform using proprietary Nanosecond Pulsed Field Ablation (nsPFA™), today announced plans t
PLSE Accelerates Cardiac Catheter Program After Breakthrough AFib Data
01:05pm, Thursday, 26'th Mar 2026
Pulse Biosciences pivots to its nPulse AFib system after strong clinical results, ramping investment to accelerate development and future commercialization.
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), pioneer of the novel nPulse™ platform using proprietary Nanosecond Pulsed Field Ablation (nsPFA™), today announced a new s
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™)
Pulse Biosciences to Present at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference
07:00am, Thursday, 05'th Mar 2026
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA
Kevin Patrick Danahy Sells 5,000 Shares of Pulse Biosciences (NASDAQ:PLSE) Stock
04:44am, Wednesday, 25'th Feb 2026
Pulse Biosciences, Inc (NASDAQ: PLSE - Get Free Report) insider Kevin Patrick Danahy sold 5,000 shares of the company's stock in a transaction dated Wednesday, February 18th. The stock was sold at an
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 20'th Feb 2026
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™)
Pulse Biosciences to Present at the 46th Annual TD Cowen Healthcare Conference
07:00am, Friday, 20'th Feb 2026
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™)
Pulse Biosciences, Inc. (PLSE) Q4 2025 Earnings Call Transcript
02:54am, Friday, 20'th Feb 2026
Pulse Biosciences, Inc. (PLSE) Q4 2025 Earnings Call Transcript
